- Conditions
- Lung Cancer
- Interventions
- BIBW 2992 (Afatinib)
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 505–528
of 9,907
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Bionic Pancreas, Usual Care
- Device · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy
- Interventions
- PF-06412562
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Lumbosacral Radicular Pain
- Interventions
- SP-102
- Drug
- Lead sponsor
- Semnur Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Boise, Idaho
- Conditions
- Solid Tumors
- Interventions
- Regorafenib, (Stivarga, BAY73-4506), Nivolumab (Opdivo)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 6
- States / cities
- Duarte, California • Aurora, Colorado • Tampa, Florida + 3 more
- Conditions
- WHIM, Warts, Hypogammaglobulinemia, Immunodeficiency, Myelokathexis
- Interventions
- Busulfan, Palifermin, Plerixafor, Filgrastim, Base-edited hematopoietic stem and progenitor cells
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 3 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Uterine Atony, Postpartum Hemorrhage
- Interventions
- Oxytocin
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- Female only
- Enrollment
- 1,798 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- HIV Infections, Sexually Transmitted Diseases
- Interventions
- PrEPmate, Dot Diary
- Other · Device
- Lead sponsor
- Public Health Foundation Enterprises, Inc.
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Miami, Florida
- Conditions
- Acute Stroke
- Interventions
- Rehabilitation Therapy on Experimental Robotic Table and standard of care, Rehabilitation Therapy as part of Standard of Care (Control)
- Device · Genetic
- Lead sponsor
- Bright Cloud International Corp
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 2
- States / cities
- North Brunswick, New Jersey • West Orange, New Jersey
- Conditions
- Pain, Drug Overdose, Opioid Use Disorders
- Interventions
- Motivational intervention, Psycho-educational control, Long-term opioid therapy informed consent
- Behavioral · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 299 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Healthy
- Interventions
- Ioforminol 160 mgI/mL, Ioforminol 200 mgI/mL, Iopamidol 300 mgI/mL
- Drug
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Coronary Artery Disease, Chest Pain, Coronary Atherosclerosis, Stress Testing
- Interventions
- Cardiac CT Angiography, Stress Imaging Test (Stress Myocardial Perfusion Study or Stress Echocardiogram)
- Procedure
- Lead sponsor
- Walter Reed Army Medical Center
- Federal
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- Study Arm - acid suppression plus feeding bundle, Conventional arm - acid suppression only
- Other
- Lead sponsor
- Sudarshan Jadcherla
- Other
- Eligibility
- 34 Weeks to 60 Weeks
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Recurrent Acute Pancreatitis, Chronic Pancreatitis
- Interventions
- Soy-tomato juice product, Will include a soy-tomato juice product to be consumed during the 4 week intervention phase. A total of about 12 ounces (administered in two small cans) of the juice will be consumed
- Dietary Supplement
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- asparaginase, cytarabine, daunorubicin hydrochloride, methotrexate, therapeutic hydrocortisone, thioguanine
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2012
- U.S. locations
- 209
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
- Conditions
- Cancer
- Interventions
- Ustekinumab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pleural Malignant Mesothelioma
- Interventions
- GC1008
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- JNJ-67896049
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- La Jolla, California • Anderson, South Carolina • Dallas, Texas
- Conditions
- Graft Versus Host Disease
- Interventions
- [18F]F-Ara-G
- Drug
- Lead sponsor
- CellSight Technologies, Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Breast Cancer
- Interventions
- IPI-504
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 7
- States / cities
- Washington D.C., District of Columbia • Boca Raton, Florida • Lake Worth, Florida + 3 more
- Conditions
- Metastatic Non-small Cell Lung Cancer, Metastatic Triple-negative Breast Cancer
- Interventions
- ADV/HSV-tk, Valacyclovir, SBRT, Pembrolizumab
- Biological · Drug · Radiation
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Injury of Ureter During Surgery (Disorder)
- Interventions
- Nizaracianine Triflutate, Placebo Comparator
- Drug
- Lead sponsor
- Curadel Surgical Innovations, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Redwood City, California • Orlando, Florida + 2 more
- Conditions
- Anthrax
- Interventions
- Ciprofloxacin and Valortim, Placebo Antibiotic and Valortim, Placebo Antibiotic and Placebo Valortim
- Drug · Other
- Lead sponsor
- PharmAthene, Inc.
- Industry
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Hemophilia A
- Interventions
- Fitusiran (SAR439774), Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC), Emicizumab
- Drug · Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Flowood, Mississippi